Socio-demographic and clinical predictors of outcome to long-term treatment with lithium in bipolar disorders: a systematic review of the contemporary literature and recommendations from the ISBD/IGSLI Task Force on treatment with lithium.

Bipolar disorder Clinical markers Depression Lithium Mania Prediction Predictors Psychiatry Response Treatment

Journal

International journal of bipolar disorders
ISSN: 2194-7511
Titre abrégé: Int J Bipolar Disord
Pays: Germany
ID NLM: 101622983

Informations de publication

Date de publication:
16 Dec 2020
Historique:
received: 09 08 2020
accepted: 08 09 2020
entrez: 17 12 2020
pubmed: 18 12 2020
medline: 18 12 2020
Statut: epublish

Résumé

To identify possible socio-demographic and clinical factors associated with Good Outcome (GO) as compared with Poor Outcome (PO) in adult patients diagnosed with Bipolar Disorder (BD) who received long-term treatment with lithium. A comprehensive search of major electronic databases was performed to identify relevant studies that included adults patients (18 years or older) with a diagnosis of BD and reported sociodemographic and/or clinical variables associated with treatment response and/or with illness outcome during long-term treatment to lithium (> = 6 months). The quality of the studies was scored using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies from the National Institute of Health. Following review, 34 publications (from 31 independent datasets) were eligible for inclusion in this review. Most of them (n = 25) used a retrospective design. Only 11 studies were graded as good or borderline good quality. Forty-three potential predictors of outcome to lithium were identified. Four factors were associated with PO to lithium: alcohol use disorder; personality disorders; higher lifetime number of hospital admissions and rapid cycling pattern. Two factors were associated with GO in patients treated with lithium: good social support and episodic evolution of BD. However, when the synthesis of findings was limited to the highest (good or borderline good) quality studies (11 studies), only higher lifetime number of hospitalization admissions remained associated with PO to lithium and no associations remained for GO to lithium. Despite decades of research on lithium and its clinical use, besides lifetime number of hospital admissions, no factor being consistently associated with GO or PO to lithium was identified. Hence, there remains a substantial gap in our understanding of predictors of outcome of lithium treatment indicating there is a need of high quality research on large representative samples.

Identifiants

pubmed: 33330966
doi: 10.1186/s40345-020-00203-3
pii: 10.1186/s40345-020-00203-3
pmc: PMC7744282
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

40

Références

Bipolar Disord. 2019 Aug;21(5):394-409
pubmed: 31112628
Ther Adv Chronic Dis. 2011 May;2(3):209-26
pubmed: 23251751
Pharmacopsychiatry. 2019 Feb;52(2):70-77
pubmed: 29486511
J Psychopharmacol. 2016 Jun;30(6):495-553
pubmed: 26979387
J Affect Disord. 2017 Jan 15;208:62-67
pubmed: 27750061
Int J Bipolar Disord. 2019 Sep 25;7(1):20
pubmed: 31552554
J Clin Psychiatry. 2002 Oct;63(10):942-7
pubmed: 12416605
Harv Rev Psychiatry. 2014 Nov-Dec;22(6):353-7
pubmed: 25377609
Int Clin Psychopharmacol. 2011 Nov;26(6):323-8
pubmed: 21876441
Lancet. 2011 Jun 18;377(9783):2093-102
pubmed: 21652063
Neuropsychobiology. 1993;27(3):138-45
pubmed: 8232828
Eur Neuropsychopharmacol. 1993 Jun;3(2):103-10
pubmed: 8364346
Compr Psychiatry. 2016 Apr;66:146-56
pubmed: 26995248
J Affect Disord. 1989 Nov-Dec;17(3):237-41
pubmed: 2529291
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Bipolar Disord. 2018 Mar;20(2):97-170
pubmed: 29536616
Int J Neuropsychopharmacol. 2003 Dec;6(4):421-4
pubmed: 14604458
Psychiatr Danub. 2016 Jun;28(2):146-53
pubmed: 27287789
Bipolar Disord. 2017 Nov;19(7):552-562
pubmed: 28691278
J Affect Disord. 2012 Feb;136(3):733-9
pubmed: 22036802
Pharmacopsychiatria. 1982 Jul;15(4):128-30
pubmed: 7146091
Int J Bipolar Disord. 2019 Jul 22;7(1):16
pubmed: 31328245
Asian J Psychiatr. 2019 Jan;39:165-168
pubmed: 29636228
J Clin Psychiatry. 1997 Nov;58(11):470-8
pubmed: 9413412
Acta Psychiatr Scand. 2019 Aug;140(2):91-93
pubmed: 31310342
Nature. 2011 Jul 06;475(7354):27-30
pubmed: 21734685
Bipolar Disord. 2005 Oct;7(5):404-17
pubmed: 16176433
J Trauma Dissociation. 2016 Jul-Sep;17(4):397-409
pubmed: 26683845
Eur Psychiatry. 2010 Jan;25(1):47-51
pubmed: 19926262
Acta Psychiatr Scand. 2019 Aug;140(2):94-115
pubmed: 31218667
Acta Psychiatr Scand. 2020 Feb;141(2):131-141
pubmed: 31667829
Acta Psychiatr Scand. 2017 Apr;135(4):319-327
pubmed: 27987204
Lancet Psychiatry. 2014 Oct;1(5):351-9
pubmed: 26360999
Bipolar Disord. 2019 Nov;21(7):582-594
pubmed: 31465619
Transl Psychiatry. 2013 May 21;3:e261
pubmed: 23695236
Front Psychiatry. 2018 Aug 21;9:360
pubmed: 30186186
Am J Psychiatry. 2006 Feb;163(2):217-24
pubmed: 16449474
Psychiatr Genet. 2013 Apr;23(2):77-81
pubmed: 23277128
Lancet. 1991 Nov 2;338(8775):1127-30
pubmed: 1682553
J Affect Disord. 2013 Feb 20;145(2):187-9
pubmed: 22939170
Aust N Z J Psychiatry. 2017 May;51(5):524-530
pubmed: 27557821
Bipolar Disord. 2018 Feb 14;:
pubmed: 29441712
Int J Neuropsychopharmacol. 2000 Mar;3(1):83-85
pubmed: 11343583
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Acta Psychiatr Scand. 1996 Jun;93(6):420-6
pubmed: 8831857
Neuropsychobiology. 1998;37(3):146-9
pubmed: 9597671
Br J Psychiatry. 1991 Jul;159:123-9
pubmed: 1888958
Bipolar Disord. 2015 Aug;17(5):543-8
pubmed: 25846854
Eur Neuropsychopharmacol. 2009 Nov;19(11):791-5
pubmed: 19577437
Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144B(6):820-3
pubmed: 17373693
J Affect Disord. 1999 Oct;55(2-3):133-42
pubmed: 10628882
Br J Psychiatry. 2014 Sep;205(3):214-20
pubmed: 25012681
J Affect Disord. 2007 Dec;104(1-3):185-90
pubmed: 17442400
J Affect Disord. 1999 Jul;54(1-2):87-96
pubmed: 10403151
Br J Psychiatry. 2001 Jun;178(Suppl 41):S184-90
pubmed: 11388960
Bipolar Disord. 2010 Aug;12(5):483-93
pubmed: 20712749
J Affect Disord. 2012 Dec 20;143(1-3):148-52
pubmed: 22749155
Int J Bipolar Disord. 2014 Dec 20;2:15
pubmed: 25530932
Bipolar Disord. 2016 Mar;18(2):174-82
pubmed: 26890465
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):204-8
pubmed: 17822820
Med J Aust. 2018 Mar 19;208(5):219-225
pubmed: 29540132
Am J Psychiatry. 1998 Jan;155(1):30-5
pubmed: 9433335

Auteurs

Diane Grillault Laroche (D)

INSERM U1144 - Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris Descartes, Paris, France.
AP-HP, DMU Neurosciences, GH Saint-Louis - Lariboisière - F. Widal, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France.

Bruno Etain (B)

INSERM U1144 - Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris Descartes, Paris, France. bruno.etain@inserm.fr.
AP-HP, DMU Neurosciences, GH Saint-Louis - Lariboisière - F. Widal, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France. bruno.etain@inserm.fr.
Faculté de Médecine, Université de Paris, Paris, France. bruno.etain@inserm.fr.
Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neurosciences, London, UK. bruno.etain@inserm.fr.

Emanuel Severus (E)

Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.

Jan Scott (J)

Faculté de Médecine, Université de Paris, Paris, France.
Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neurosciences, London, UK.
Academic Psychiatry, Institute of Neuroscience, Newcastle University, Newcastle, UK.

Frank Bellivier (F)

INSERM U1144 - Optimisation Thérapeutique en Neuropsychopharmacologie, Université de Paris Descartes, Paris, France.
AP-HP, DMU Neurosciences, GH Saint-Louis - Lariboisière - F. Widal, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France.
Faculté de Médecine, Université de Paris, Paris, France.

Classifications MeSH